Analysed CARTESIAN THERAPEUTICS INC (RNAC:NASDAQ) News Sources
Myasthenia Gravis Market Set to Surpass USD 16 Billion by 2036, Fueled by Rising Diagnosed Prevalence and Wave of Targeted Biologic Approvals | DelveInsight
18-05-2026
yahoo.com
Emerging Hope in Multiple Myeloma Market: 7 Late-Stage Therapies Nearing the Finish Line | DelveInsight
25-05-2026
yahoo.com
Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027
26-05-2026
yahoo.com
Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases
09-06-2026
yahoo.com
AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine
10-06-2026
biopharmadive.com
Kiniksa Pharmaceuticals International, plc (KNSA) Surges 5.4%: Is This an Indication of Further Gains?
30-06-2026
yahoo.com
What is the current price of CARTESIAN THERAPEUTICS INC (RNAC:NASDAQ)?
The current price of CARTESIAN THERAPEUTICS INC (RNAC:NASDAQ) is $9.46.
CARTESIAN THERAPEUTICS INC (RNAC:NASDAQ) absolute price change since previous trading day?
The absolute price change of CARTESIAN THERAPEUTICS INC (RNAC:NASDAQ) since the previous trading day is $-0.21.
CARTESIAN THERAPEUTICS INC (RNAC:NASDAQ) percentage price change since previous trading day?
The percentage price change of CARTESIAN THERAPEUTICS INC (RNAC:NASDAQ) since the previous trading day is -2.1717%.
What is the most recent average sentiment score for CARTESIAN THERAPEUTICS INC (RNAC:NASDAQ)?
The most recent average sentiment score for CARTESIAN THERAPEUTICS INC (RNAC:NASDAQ) is 73 out of 100.
What is the most recent average sentiment for CARTESIAN THERAPEUTICS INC (RNAC:NASDAQ)?
The most recent sentiment for CARTESIAN THERAPEUTICS INC (RNAC:NASDAQ) is .
SEC-8K** Filing Available For CARTESIAN THERAPEUTICS INC (RNAC:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.